Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Cann Group ( (AU:CAN) ) is now available.
Cann Group Limited, a medicinal cannabis producer based in Australia, has been sharpening its focus on high-quality, competitively priced flower for B2B customers and branded products for patients. Its wholesale flower sales now account for 44% of revenue, while own-brand dried flower remains a core contributor, even as oil sales decline in line with broader market trends.
In the half year to 31 December 2025, the company cut its total debt from $70 million to $14.8 million after a major restructuring, including a large write-down linked to a lender exit, materially strengthening its balance sheet. Revenue slipped 7% to $4.52 million amid subdued market prescribing and refinance-related uncertainty, but B2B sales rose 26%, operating expenses fell sharply, and operating cash flow was near breakeven, positioning Cann to pursue stronger second-half growth backed by secured Q3 orders and a path toward EBITDA breakeven.
The most recent analyst rating on (AU:CAN) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Cann Group stock, see the AU:CAN Stock Forecast page.
More about Cann Group
Cann Group Limited is an Australian medicinal cannabis producer focused on supplying dried flower and oil products to pharmaceutical and healthcare markets. The company operates primarily through B2B wholesale channels and its own Botanitech and upcoming Mallee Bloom brands, targeting both domestic prescribers and customers exporting to international medical cannabis markets.
Average Trading Volume: 11,539,069
Technical Sentiment Signal: Sell
Current Market Cap: A$9.53M
For a thorough assessment of CAN stock, go to TipRanks’ Stock Analysis page.